Andere Sprachen Poolbeg Pharma PLC

Aktien

Verzögert London S.E. Andere Börsenplätze 17:22:34 04.06.2024			% 5 Tage	% 1. Jan.
13,62 ^GBX	-4,39 %		+2,87 %	+49,48 %

01.05.	Poolbeg Pharma erhält vollständiges US-Patent für Immunomodulator II	MT
01.05.	Poolbeg Pharma feiert die vollständige Patenterteilung für Immunomodulator II	AN

Poolbeg Pharma plc - Annual Report and AGM Notice	10.05.
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office	08.05.
Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	01.05.
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	01.05.
Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug	01.05.
Poolbeg Pharma plc - Appointment of Joint Broker	01.05.
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	01.05.
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	30.04.
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30.04.
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	30.04.
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	20.03.
Poolbeg Pharma plc Announces POLB 001 US Patent Update	20.03.
Poolbeg Pharma plc - Director Share Purchase	23.02.
Poolbeg Pharma plc - Director Share Purchase	20.02.
Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale	20.02.
Diversified Energy offers dividend alternative	15.02.
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	15.02.
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	15.02.
Katoro Gold launches fundraising, eyes board shake-up	12.02.
Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies	12.02.

Keine Ergebnisse zu dieser Suche